Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
74.94
+1.89 (2.59%)
At close: Mar 9, 2026, 4:00 PM EDT
74.71
-0.23 (-0.31%)
After-hours: Mar 9, 2026, 6:59 PM EDT

Apogee Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-255.84-182.15-83.99-43.4
Depreciation & Amortization
1.420.19--
Loss (Gain) From Sale of Investments
-7.5-12.24-3.07-
Stock-Based Compensation
46.2823.336.12.34
Other Operating Activities
3.681.690.0912.44
Change in Accounts Payable
0.15-1.071.610.46
Change in Other Net Operating Assets
-15.63-0.934.4910.25
Operating Cash Flow
-227.45-171.17-74.76-17.92
Capital Expenditures
-5.15-1.15-0.17-
Investment in Securities
-174.43-299.31-273.74-
Investing Cash Flow
-179.57-300.46-273.91-
Issuance of Common Stock
396.49495.11315.39-
Other Financing Activities
----0.75
Financing Cash Flow
396.49495.11315.39183.62
Net Cash Flow
-10.5323.47-33.28165.7
Free Cash Flow
-232.6-172.33-74.93-17.92
Free Cash Flow Per Share
-3.83-3.12-3.00-7.28
Levered Free Cash Flow
-138.98-113.42-45.5-
Unlevered Free Cash Flow
-138.98-113.42-45.5-
Change in Working Capital
-15.48-26.1110.71
Source: S&P Capital IQ. Standard template. Financial Sources.